BIIB•benzinga•
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
Summary
Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer's treatment.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 16, 2025 by benzinga